Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulse Biosciences Inc PLSE

Healthcare Medical Devices
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it... see more

Recent & Breaking News (NDAQ:PLSE)

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Business Wire October 31, 2024

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

Business Wire October 30, 2024

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Business Wire October 30, 2024

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

Business Wire October 21, 2024

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

Business Wire August 12, 2024

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Business Wire August 12, 2024

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Business Wire August 8, 2024

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Business Wire August 1, 2024

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Pulse Biosciences, Inc. (NASDAQ: PLSE)

PR Newswire August 1, 2024

Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024

Business Wire July 29, 2024

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Business Wire July 8, 2024

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

Business Wire July 3, 2024

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

Business Wire June 28, 2024

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

Business Wire May 20, 2024

Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA(TM)) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

Business Wire May 16, 2024

Pulse Biosciences Enhances Executive Leadership Team

Business Wire May 14, 2024

Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

Business Wire May 9, 2024

Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results

Business Wire May 7, 2024

Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000

Business Wire May 2, 2024

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024

Business Wire April 24, 2024